Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.79 |
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518738 | 1.00 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1 | |
| SCHEMBL3516203 | 0.91 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1 | |
| SCHEMBL3523057 | 0.91 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1 | |
| SCHEMBL3122984 | 0.91 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1 | |
| SCHEMBL3516899 | 0.89 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1 | |
| SCHEMBL3518339 | 0.89 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1 | |
| SCHEMBL3749305 | 0.89 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1 | |
| SCHEMBL29360648 | 0.88 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL3117563 | 0.88 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL30132824 | 0.88 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | HSP90AA1 659/4885HSP90AB1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.